Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SARS-CoV-2 Recombinant Spike Protein,Advax-SM
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Vaxine
Deal Size : Not Applicable
Deal Type : Not Applicable
CinnaGen Protein Subunit Covid-19 Vaccine Phase III Results Likely Within Two Months
Details : SpikoGen features the SARS-CoV-2 spike protein and Vaxine’s own Advax-SM adjuvant. The placebo-controlled SpikoGen trial has coprimary endpoints investigating the occurrence of symptomatic Covid-19 and severe Covid-19, with both endpoints.
Brand Name : SpikoGen
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 16, 2021
Lead Product(s) : SARS-CoV-2 Recombinant Spike Protein,Advax-SM
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Vaxine
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?